Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

Inebilizumab showed significant efficacy in improving MG-ADL and QMG scores in gMG patients compared to placebo over 26 weeks. The trial included 238 patients, with 80% AChR+ and 20% MuSK+, and ...

The ADL claims it identified a network of Wikipedia ... “The big problem is scale. Is there enough human effort to make sure things are done well? And that’s just an ongoing challenge ...

Feeder shipping offers a much higher return than investment in large container ships, according to a report by Arthur D.

on a patient-reported symptoms and activity scale called MG-ADL. Participants offered a placebo showed a 3.6-point improvement on the same scale. The benefit for both doses of batoclimab over ...

assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. On ADAS-COG12 (cognitive scale, where lower numbers mean less cognitive impairment), scores rose by 4.97 and 5.26 ...

The primary outcome was functional independence (defined as a score of 0 to 2 on the modified Rankin scale; scores range from 0 to 6, with higher scores indicating greater disability) at 90 days.